- Home
- ROIV vs DCI Comparison
ROIV vs DCI Comparison
Compare ROIV & DCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ROIV
- DCI
- Stock Information
- Founded
- ROIV 2014
- DCI 1915
- Country
- ROIV United Kingdom
- DCI United States
- Employees
- ROIV N/A
- DCI N/A
- Industry
- ROIV Biotechnology: Pharmaceutical Preparations
- DCI Pollution Control Equipment
- Sector
- ROIV Health Care
- DCI Industrials
- Exchange
- ROIV Nasdaq
- DCI Nasdaq
- Market Cap
- ROIV 8.6B
- DCI 9.8B
- IPO Year
- ROIV N/A
- DCI 1987
- Fundamental
- Price
- ROIV $20.23
- DCI $86.49
- Analyst Decision
- ROIV Strong Buy
- DCI Hold
- Analyst Count
- ROIV 8
- DCI 3
- Target Price
- ROIV $21.06
- DCI $80.33
- AVG Volume (30 Days)
- ROIV 8.5M
- DCI 571.0K
- Earning Date
- ROIV 11-10-2025
- DCI 12-02-2025
- Dividend Yield
- ROIV N/A
- DCI 1.42%
- EPS Growth
- ROIV N/A
- DCI N/A
- EPS
- ROIV N/A
- DCI 3.05
- Revenue
- ROIV $23,233,000.00
- DCI $3,690,900,000.00
- Revenue This Year
- ROIV N/A
- DCI $4.36
- Revenue Next Year
- ROIV $320.50
- DCI $4.52
- P/E Ratio
- ROIV N/A
- DCI $28.36
- Revenue Growth
- ROIV N/A
- DCI 2.92
- 52 Week Low
- ROIV $8.73
- DCI $57.45
- 52 Week High
- ROIV $20.30
- DCI $86.76
- Technical
- Relative Strength Index (RSI)
- ROIV 81.36
- DCI 70.60
- Support Level
- ROIV $19.30
- DCI $82.58
- Resistance Level
- ROIV $20.09
- DCI $84.88
- Average True Range (ATR)
- ROIV 0.59
- DCI 1.42
- MACD
- ROIV 0.11
- DCI 0.17
- Stochastic Oscillator
- ROIV 97.95
- DCI 94.77
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
About DCI Donaldson Company Inc.
Donaldson is a leading manufacturer of filtration systems and replacement parts (including air filtration systems, liquid filtration systems, and dust, fume, and mist collectors). The company serves a diverse range of end markets, including construction, mining, agriculture, truck, and industrial. Its business is organized into three segments: mobile solutions, industrial solutions, and life sciences. Donaldson generated approximately $3.7 billion in revenue in its fiscal 2025.